Sep 2011

Home >> Clinical Trials News Archive >> 2011 >> Sep 2011
S&P UPGRADES ISRAEL TO A+. Standard & Poor's upgraded Israel's long-term foreign-currency sovereign rating from A to A+ with a "Stable" outlook, citing Israel's "prosperous and resilient economy, strong institutions, ongoing fiscal consolidation, and robust external performance. The rating agency also reaffirmed Israel's local currency rating at AA-.

2010 sees rise in civilian R&D spending. National spending on civilian research and development totals NIS 35.8 billion, making up 4.4% of GDP last year.

Israel ranked 22nd in global competitiveness. Israel rose two places from last year in the World Economic Forum rankings, and was up five places from 2009.
 
Hebrew University ranks 57th in world. Tel Aviv University, Weizmann Institute and Haifa's Technion also placed on list of best 150 universities worldwide, in annual ranking compiled in China

On September 7, 2011, the Office for Human Subject Protections (OHRP) and the Food and Drug Administration (FDA) announced in the Federal Register the availability of a joint draft document entitled, "Guidance on Exculpatory Language in Informed Consent," and are inviting public comments on that document.
 
Integrated CRO alliances growing but poorly executed. Results from a new CenterWatch survey show CROs generally believe that while the prevalence of integrated alliances with sponsors will grow in the next three to five years, many sponsors fall short when managing these more sophisticated relationships.

Survey: CROs increasing prices. Survey results have again surprised analysts by showing prices charged by CROs, particularly to large pharma, have increased in recent months, according to Outsourcing-Pharma.
 
HHS Announcement to Extend the Comment Period on Proposal to Improve Rules Protecting Human Research Subjects (Sept. 1, 2011)